Insider Trading Alert - PRXL, TRAK, OPK, SSTK And ELX Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Feb. 5, 2014, 146 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $51.84 to $26,546,700.00.

Highlighted Stocks Traded by Insiders:

Parexel International Corporation (PRXL) - FREE Research Report

Goldberg Mark A who is President & COO at Parexel International Corporation sold 13,529 shares at $48.70 on Feb. 5, 2014. Following this transaction, the President & COO owned 105,088 shares meaning that the stake was reduced by 11.41% with the 13,529-share transaction.

The shares most recently traded at $49.93, up $1.23, or 2.46% since the insider transaction. Historical insider transactions for Parexel International Corporation go as follows:

  • 4-Week # shares bought: 5,000
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 7,000
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 12,000

The average volume for Parexel International Corporation has been 678,300 shares per day over the past 30 days. Parexel International Corporation has a market cap of $2.8 billion and is part of the health care sector and health services industry. Shares are up 8.23% year-to-date as of the close of trading on Wednesday.

PAREXEL International Corporation, a biopharmaceutical services company, provides clinical research, medical communications, consulting, commercialization, and advanced technology products and services to the pharmaceutical, biotechnology, and medical device industries worldwide. The company has a P/E ratio of 24.9. Currently there are 5 analysts that rate Parexel International Corporation a buy, 1 analyst rates it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PRXL - FREE

TheStreet Quant Ratings rates Parexel International Corporation as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, reasonable valuation levels, solid stock price performance and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Parexel International Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Dealertrack Technologies (TRAK) - FREE Research Report

Sundaram Rajesh who is EVP, Dealer Solutions, Sales at Dealertrack Technologies sold 8,316 shares at $43.72 on Feb. 5, 2014. Following this transaction, the EVP, Dealer Solutions, Sales owned 91,064 shares meaning that the stake was reduced by 8.37% with the 8,316-share transaction.

The shares most recently traded at $45.49, up $1.77, or 3.88% since the insider transaction. Historical insider transactions for Dealertrack Technologies go as follows:

  • 4-Week # shares sold: 2,000
  • 12-Week # shares sold: 2,000
  • 24-Week # shares sold: 8,000

The average volume for Dealertrack Technologies has been 351,900 shares per day over the past 30 days. Dealertrack Technologies has a market cap of $1.9 billion and is part of the technology sector and internet industry. Shares are down 8.24% year-to-date as of the close of trading on Wednesday.

Dealertrack Technologies, Inc. provides Web-based software solutions to the automotive retail industry in the United States and Canada. The company has a P/E ratio of 183.8. Currently there are 4 analysts that rate Dealertrack Technologies a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on TRAK - FREE

TheStreet Quant Ratings rates Dealertrack Technologies as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in net income, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Dealertrack Technologies Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Opko Health (OPK) - FREE Research Report

Frost Phillip Md Et Al who is CEO & Chairman at Opko Health bought 43,400 shares at $7.62 on Feb. 5, 2014. Following this transaction, the CEO & Chairman owned 138.7 million shares meaning that the stake was reduced by 0.03% with the 43,400-share transaction.

The shares most recently traded at $7.61, down $0.01, or 0.11% since the insider transaction. Historical insider transactions for Opko Health go as follows:

  • 4-Week # shares bought: 20,000
  • 4-Week # shares sold: 46,730
  • 12-Week # shares bought: 30,000
  • 12-Week # shares sold: 46,730
  • 24-Week # shares bought: 30,000
  • 24-Week # shares sold: 46,730

The average volume for Opko Health has been 4.5 million shares per day over the past 30 days. Opko Health has a market cap of $3.1 billion and is part of the health care sector and health services industry. Shares are down 10.19% year-to-date as of the close of trading on Wednesday.

Opko Health, Inc., a pharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. Currently there are 3 analysts that rate Opko Health a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OPK - FREE

TheStreet Quant Ratings rates Opko Health as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and weak operating cash flow. Get the full Opko Health Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Shutterstock (SSTK) - FREE Research Report

Semmelbauer Thilo who is President and COO at Shutterstock sold 5,000 shares at $78.06 on Feb. 5, 2014. Following this transaction, the President and COO owned 387,649 shares meaning that the stake was reduced by 1.27% with the 5,000-share transaction.

The shares most recently traded at $78.71, up $0.65, or 0.83% since the insider transaction. Historical insider transactions for Shutterstock go as follows:

  • 4-Week # shares sold: 5,000
  • 12-Week # shares sold: 5,000
  • 24-Week # shares sold: 4.2 million

The average volume for Shutterstock has been 157,700 shares per day over the past 30 days. Shutterstock has a market cap of $2.8 billion and is part of the services sector and diversified services industry. Shares are down 6.92% year-to-date as of the close of trading on Wednesday.

Shutterstock, Inc. operates an online marketplace for commercial digital imagery. The company has a P/E ratio of 97.9. Currently there are 4 analysts that rate Shutterstock a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SSTK - FREE

TheStreet Quant Ratings rates Shutterstock as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, notable return on equity and robust revenue growth. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share and unimpressive growth in net income. Get the full Shutterstock Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Emulex Corporation (ELX) - FREE Research Report

Mccluney James M who is Director at Emulex Corporation sold 150,000 shares at $7.32 on Feb. 5, 2014. Following this transaction, the Director owned 240,427 shares meaning that the stake was reduced by 38.42% with the 150,000-share transaction.

The shares most recently traded at $7.39, up $0.07, or 0.99% since the insider transaction. Historical insider transactions for Emulex Corporation go as follows:

  • 4-Week # shares sold: 11,412
  • 12-Week # shares sold: 261,412
  • 24-Week # shares sold: 285,188

The average volume for Emulex Corporation has been 1.6 million shares per day over the past 30 days. Emulex Corporation has a market cap of $591.1 million and is part of the technology sector and computer hardware industry. Shares are up 1.54% year-to-date as of the close of trading on Wednesday.

Emulex Corporation provides network connectivity, monitoring, and management products for networks that support enterprise, cloud, government, and telecommunications worldwide. Currently there are 2 analysts that rate Emulex Corporation a buy, 1 analyst rates it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ELX - FREE

TheStreet Quant Ratings rates Emulex Corporation as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income and disappointing return on equity. Get the full Emulex Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists